Andrew Hindman, Theravance CFO
Theravance, Innoviva sell royalty rights on GSK's Trelegy to Royalty Pharma for $1.3B upfront
Royalty Pharma is shelling out the big bucks to get its hands on royalties for a GSK drug.
Theravance Biopharma put out word Wednesday that …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
